Researchers at the University of Queensland have developed a framework to test AI reliability in discovering new antibiotics, tackling the global crisis of antimicrobial resistance.
A New Approach to AI in Drug Discovery
Dr. Abdulmujeeb Onawole, from UQ's Centre for Superbug Solutions, highlighted a major barrier to trusting AI in medical research: the 'black box' problem. AI often cannot explain its reasoning, which hinders trust in its recommendations. This new framework is designed to open that black box.
Testing the Framework
The research team tested their framework on three different AI models. They used datasets of chemical compounds previously evaluated against the superbug Staphylococcus aureus.
The framework specifically examined whether the AI could:
- Correctly identify important drug structures.
- Interpret 'activity cliffs'—small chemical changes that can drastically alter a drug's effectiveness.
The Results
Dr. Johannes Zuegg, also from UQ's Centre for Superbug Solutions, reported that all three AI models were effective at identifying known antibiotic structures. However, they varied significantly in their ability to explain what makes a molecule active or inactive.
The study was published in the Journal of Cheminformatics.
Why This Matters
Antimicrobial resistance, including antibiotic resistance, is a major threat to global healthcare. It limits effective treatment options against multidrug-resistant pathogens. This framework aims to speed up the integration of AI into antibiotic research, helping scientists make more informed decisions in the fight against superbugs.